Introduction to Myeloma Why Promise
Let's dive into the details surrounding Myeloma Why Promise. Annie Cowan, BA, Dana-Farber Cancer Institute, Boston, MA, outlines the aims, methods and results of the
Myeloma Why Promise Comprehensive Overview
Learn how the groundbreaking Dana-Farber's Dr. Irene Ghobrial provides an overview of the Watch the full course and our most up-to-date content here: https://linktr.ee/HealthTreeUniversity Create a free account to track ...
In this video, Salomon Manier, MD, PhD, Lille University, Lille, France, shares some insights into treatment strategies for late-stage ...
Summary & Highlights for Myeloma Why Promise
- Noopur Raje, MD, Massachusetts General Hospital, Boston, MA, comments on the current state of next-generation CAR constructs ...
- Nearly all patients with multiple
- The Phase I study (NCT03110822) of ruxolitinib in combination with lenalidomide and methylprednisolone shows
- Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, shares some insights into the progress that has been made in ...
- This public webinar aired live on Monday, March 30th at 5:00 EST. To learn more about the
That wraps up our extensive overview of Myeloma Why Promise.
